XERS insider transaction filings

Xeris Biopharma Holdings, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen XERS transaction legs live →

FiledFormInsiderReported transactionsSource
2026-08-214Shannon John Patrick Jr — See Remarks, DirectorTax withholding (F): 36,645 @ $8.08EDGAR
2026-08-214McCulloch Kevin — See RemarksTax withholding (F): 21,918 @ $8.08EDGAR
2026-08-124Pieper Steven — See RemarksSale (S): 5,000 @ $8.50EDGAR
2026-08-044McCulloch Kevin — See RemarksSale (S): 15,000 @ $8.02EDGAR
2026-08-044Hecht Beth — See RemarksSale (S): 16,666 @ $8.01EDGAR
2026-07-074Pieper Steven — See RemarksSale (S): 17,400 @ $8.50 · Sale (S): 27,600 @ $8.52EDGAR
2026-07-024McCulloch Kevin — See RemarksSale (S): 90,000 @ $8.03EDGAR
2026-07-024KREHER NERISSA — DirectorGrant/award (A): 33,582 @ $0 · Grant/award (A): 37,910 (derivative) @ $8EDGAR
2026-07-024Hecht Beth — See RemarksSale (S): 16,666 @ $8.03EDGAR
2026-06-054Brady James Aloysius — DirectorGrant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-054HALKUFF DAWN — DirectorSale (S): 20,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-054BORMANN-KENNEDY BARBARA-JEAN ANNE — DirectorSale (S): 16,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-054Kong Garheng — DirectorGrant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-054JOHNSON JOHN — DirectorSale (S): 15,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-054PERSKY MARLA — DirectorSale (S): 15,500 @ $5.90 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15EDGAR
2026-06-024Hecht Beth — See RemarksSale (S): 16,667 @ $6.06EDGAR
2026-05-014Hecht Beth — See RemarksSale (S): 16,667 @ $6.23EDGAR
2026-04-034Hecht Beth — See RemarksSale (S): 16,667 @ $5.99EDGAR
2026-04-014Brady James Aloysius — DirectorSale (S): 10,834 @ $5.54EDGAR
2026-03-164McCulloch Kevin — See RemarksOption exercise (M): 48,894 @ $4.09 · Option exercise (M): 4 @ $3.94 · Option exercise (M): 48,894 (derivative) @ $4.09 · Option exercise (M): 4 (derivative) @ $3.94EDGAR
2026-03-054Pieper Steven — See RemarksOption exercise (M): 27,891 @ $4.09 · Option exercise (M): 14,036 @ $5.93 · Option exercise (M): 27,891 (derivative) @ $0 · Option exercise (M): 14,036 (derivative) @ $0EDGAR
2026-03-044Hecht Beth — See RemarksSale (S): 16,567 @ $6.24 · Sale (S): 100 @ $7.06EDGAR
2026-02-254Nguyen Anh Tu — See RemarksTax withholding (F): 29,300 @ $6.88EDGAR
2026-02-024Nguyen Anh Tu — See RemarksGrant/award (A): 121,293 @ $0 · Grant/award (A): 162,162 (derivative) @ $0EDGAR
2026-02-024McCulloch Kevin — See RemarksGrant/award (A): 168,463 @ $0 · Tax withholding (F): 68,454 @ $7.36 · Tax withholding (F): 30,289 @ $7.36 · Tax withholding (F): 27,319 @ $7.36 · Grant/award (A): 225,225 (derivative) @ $0EDGAR
2026-02-024Pieper Steven — See RemarksGrant/award (A): 154,986 @ $0 · Tax withholding (F): 111,765 @ $7.36 · Tax withholding (F): 66,450 @ $7.36 · Tax withholding (F): 27,319 @ $7.36 · Grant/award (A): 207,207 (derivative) @ $0EDGAR
2026-02-024Hecht Beth — See RemarksGrant/award (A): 121,293 @ $0 · Tax withholding (F): 98,375 @ $7.36 · Tax withholding (F): 46,914 @ $7.36 · Tax withholding (F): 24,266 @ $7.36 · Sale (S): 16,667 @ $7.45 · Grant/award (A): 162,162 (derivative) @ $0EDGAR
2026-02-024Shannon John Patrick Jr — See Remarks, DirectorGrant/award (A): 478,436 @ $0 · Tax withholding (F): 118,134 @ $7.36 · Tax withholding (F): 111,621 @ $7.36 · Tax withholding (F): 110,750 @ $7.36 · Grant/award (A): 639,639 (derivative) @ $0EDGAR
2026-01-094McCulloch Kevin — See RemarksSale (S): 15,000 @ $8EDGAR
2026-01-064Shannon John Patrick Jr — See Remarks, DirectorSale (S): 24,907 @ $7.08 · Option exercise (M): 64,265 @ $1.55 · Option exercise (M): 25,136 @ $1.55 · Option exercise (M): 2,900 @ $3.94 · Option exercise (M): 64,265 (derivative) @ $0 · Option exercise (M): 25,136 (derivative) @ $0 · +1 moreEDGAR
2026-01-054Hecht Beth — See RemarksSale (S): 16,667 @ $7.43EDGAR
2025-12-194JOHNSON JOHN — DirectorSale (S): 135,400 @ $7.22EDGAR
2025-12-154BORMANN-KENNEDY BARBARA-JEAN ANNE — DirectorSale (S): 15,000 @ $7.09EDGAR
2025-12-024Hecht Beth — See RemarksSale (S): 16,667 @ $7.01EDGAR
2025-11-174Shannon John Patrick Jr — See Remarks, DirectorOption exercise (M): 8,970 @ $1.55 · Sale (S): 23,242 @ $7.46 · Option exercise (M): 87,100 @ $1.55 · Option exercise (M): 8,970 (derivative) @ $0 · Option exercise (M): 87,100 (derivative) @ $0EDGAR
2025-11-134Hecht Beth — See RemarksSale (S): 16,667 @ $7.40EDGAR
2025-10-034McCulloch Kevin — See RemarksTax withholding (F): 733 @ $8.31EDGAR
2025-09-154McCulloch Kevin — See RemarksOther (J): 2,000 @ $0EDGAR
2025-09-124PERSKY MARLA — DirectorSale (S): 15,500 @ $7.72EDGAR
2025-08-294SHERMAN JEFFREY W — DirectorOption exercise (M): 47,040 @ $6.66 · Sale (S): 42,232 @ $7.92 · Option exercise (M): 47,040 (derivative) @ $0EDGAR
2025-08-154JOHNSON JOHN — DirectorSale (S): 107,500 @ $7.32EDGAR
2025-08-134HALKUFF DAWN — DirectorSale (S): 42,500 @ $7.28EDGAR
2025-08-044McCulloch Kevin — See RemarksTax withholding (F): 14,651 @ $5.38EDGAR
2025-08-044Shannon John Patrick Jr — See Remarks, DirectorTax withholding (F): 36,918 @ $5.38EDGAR
2025-06-164McCulloch Kevin — See RemarksPurchase (P): 25,000 @ $4.38EDGAR
2025-06-044HALKUFF DAWN — DirectorGrant/award (A): 50,000 @ $0EDGAR
2025-06-044BORMANN-KENNEDY BARBARA-JEAN ANNE — DirectorGrant/award (A): 50,000 @ $0EDGAR
2025-06-044Kong Garheng — DirectorGrant/award (A): 50,000 @ $0EDGAR
2025-06-044JOHNSON JOHN — DirectorGrant/award (A): 50,000 @ $0EDGAR
2025-06-044PERSKY MARLA — DirectorGrant/award (A): 50,000 @ $0EDGAR

Recent 8-K events — Xeris Biopharma Holdings, Inc.

FiledFormItems reportedSource
2026-08-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-178-K3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
EDGAR
2026-06-308-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-118-K3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-058-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-078-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-04-218-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-03-028-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-278-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-01-088-K2.02 — Results of Operations and Financial ConditionEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=XERS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →